{"id":"NCT01362140","sponsor":"Amgen","briefTitle":"Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","officialTitle":"A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12-21","primaryCompletion":"2015-02-11","completion":"2017-09-14","firstPosted":"2011-05-30","resultsPosted":"2016-12-05","lastUpdate":"2017-12-19"},"enrollment":147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["MDS"],"interventions":[{"type":"DRUG","name":"Darbepoetin alfa","otherNames":["Aranesp"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Darbepoetin alfa","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective was to assess the superiority of darbepoetin alfa versus placebo on the incidence of red blood cell transfusions during the 24-week double-blind treatment period in anemic patients with low or intermediate-1 risk MDS.","primaryOutcome":{"measure":"Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period","timeFrame":"Week 5 to Week 25","effectByArm":[{"arm":"Placebo","deltaMin":59.2,"sd":null},{"arm":"Darbepoetin Alfa","deltaMin":36.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.008"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":32},"locations":{"siteCount":72,"countries":["Austria","Belgium","Czechia","France","Germany","Greece","Italy","Spain","Switzerland"]},"refs":{"pmids":["28626220"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":48},"commonTop":["Fatigue","Asthenia","Nasopharyngitis","Dyspnoea exertional","Pyrexia"]}}